Diltiazem Treatment for Preclinical Hypertrophic Cardiomyopathy Mutation Carriers: A Pilot Randomized Trial to Modify Disease Expression

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is caused by sarcomere mutations and characterized by left ventricular hypertrophy (LVH) with increased risk of heart failure and sudden death. HCM typically cannot be diagnosed early in life, although subtle phenotypes are present. Animal studies indica...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JACC Heart Fail
Main Authors: Ho, Carolyn Y., Lakdawala, Neal K., Cirino, Allison L., Lipshultz, Steven E., Sparks, Elizabeth, Abbasi, Siddique A., Kwong, Raymond Y., Antman, Elliott M., Semsarian, Christopher, González, Arantxa, López, Begoña, Diez, Javier, Orav, E. John, Colan, Steven D., Seidman, Christine E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4323670/
https://ncbi.nlm.nih.gov/pubmed/25543971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jchf.2014.08.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados